


Concord Biotech

14 June 2007 | News



Concord Biotech



Concord Biotech Ltd (CBL), an R&D based biotechnology company, having state-of-the-art fermentation facility, is one of the major players in the statins and immunosuppressants market in India. Its revenue in 2006-07 touched Rs 45 crore against last year's sales revenue of Rs 18 crore. It is expected to cross Rs 100 crore mark by this financial year, as it has commissioned a Vancomycin plant in March this year. Besides antibiotics, immunosuppressants and statins contribute a major chunk to its revenues. About 40 percent of the revenue is from exports.

CBL is the largest producer of Penicillin-G Amidase enzyme. It has been exporting this enzyme to a number of companies in China, Europe and the US besides having a 90 percent market share in India. CBL also produces and exports Lovastatin and Tacrolimus to Europe and other countries. It will shortly start the production of Simvastatin and Pravastatin at its newly USFDA approved facility.

CBL also undertakes custom synthesis projects in biotechnology. CBL has been adding on two new manufacturing blocks. At present it has seven dedicated blocks for enzyme, statins and immunosuppressants covering a built up area of 12-13 acres from just one and a half acres in 2000. Then it started producing Tacrolimus, Mycophenolate Mofetil, Mycophenolate Sodium. Later on, it added Pravastatin, Sirolimus to its product basket. It has dedicated plants for all these different products and has been supplying all these products to the US and most of the other regulated markets. CBL is the only company in the world, which is making all the immunosuppressants. It has taken all the necessary steps to maintain the balance of ecosystem by setting up a sophisticated facility for the treatment of the effluents generated from the process.